The immature electrophysiological phenotype of iPSC-CMs still hampers in vitro drug screening: Special focus on I K1
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Preclinical drug screens are not based on human physiology, possibly complicating predictions on cardiotoxicity. Drug screening can be humanised with in vitro assays using human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). However, in contrast to adult ventricular cardiomyocytes, iPSC-CMs beat spontaneously due to presence of the pacemaking current If and reduced densities of the hyperpolarising current IK1. In adult cardiomyocytes, IK1 finalises repolarisation by stabilising the resting membrane potential while also maintaining excitability. The reduced IK1 density contributes to proarrhythmic traits in iPSC-CMs, which leads to an electrophysiological phenotype that might bias drug responses. The proarrhythmic traits can be suppressed by increasing IK1 in a balanced manner. We systematically evaluated all studies that report strategies to mature iPSC-CMs and found that only few studies report IK1 current densities. Furthermore, these studies did not succeed in establishing sufficient IK1 levels as they either added too little or too much IK1. We conclude that reduced densities of IK1 remain a major flaw in iPSC-CMs, which hampers their use for in vitro drug screening.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
O'Hara, T., Virág, L., Varró, A., & Rudy, Y. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002061 · Cited by 1,196
Biowire: a platform for maturation of human pluripotent stem cell–derived cardiomyocytes
Nunes, S. S., Miklas, J. W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2524 · Cited by 952
Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes
Yang, X., Pabon, L., & Murry, C. E. (2014) · Circulation Research · doi:10.1161/circresaha.114.300558 · Cited by 939 · cited 1×
“…to temporally and spatially recapitulating cardiogenesis, introducing factors such as retinoic acid, Vascular Endothelial Growth Factor (VEGF), Insulin Growth Factor (IGF)-1 and Activin A has improved the purity of cardiomyocytes (Calderon, Bardot, & Dubois, 2016, Yang, Pabon, & Murry, 2014).”
Karakikes, I., Ameen, M., Termglinchan, V., & Wu, J. C. (2015) · Circulation Research · doi:10.1161/circresaha.117.305365 · Cited by 478
Evolution of strategies to improve preclinical cardiac safety testing
Gintant, G., Sager, P. T., & Stockbridge, N. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.34 · Cited by 407 · cited 1×
“The need for human cardiac models has led to the development of the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative (Gintant, Sager,&Stockbridge, 2016).”
Asimaki, A., Kapoor, S., Plovie, E., Karin Arndt, A., Adams, E., Liu, Z., James, C. A., Judge, D. P., Calkins, H., Churko, J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008008 · Cited by 274 · cited 1×
“Interactions with cardio-myocyte speci fi c proteins have been investigated in zebra fi sh, where I K1 is downregulated after knockout of the desmosomal protein plako-philin-2 (Asimaki et al., 2014).”
Maturing human pluripotent stem cell-derived cardiomyocytes in human engineered cardiac tissues
Feric, N. T., & Radisic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.04.019 · Cited by 247
Matsa, E., Burridge, P. W., Yu, K.-H., Ahrens, J. H., Termglinchan, V., Wu, H., Liu, C., Shukla, P., Sayed, N., Churko, J. M., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.07.006 · Cited by 164
Tzatzalos, E., Abilez, O. J., Shukla, P., & Wu, J. C. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.010 · Cited by 162 · cited 1×
“…stimulation (Zhu et al., 2014), co-cultures with non-cardiomyocytes (Ravenscroft, Pointon, Williams, Cross, & Sidaway, 2016), over-expression, prolonged cell culture (Tzatzalos, Abilez, Shukla, & Wu, 2016), and 3D engineered heart tissues (EHTs) (Feric & Radisic, 2016; Fong et al., 2016).”
Physical developmental cues for the maturation of human pluripotent stem cell-derived cardiomyocytes
Zhu, R., Blazeski, A., Poon, E., Costa, K. D., Tung, L., & Boheler, K. R. (2014) · Stem Cell Research & Therapy · doi:10.1186/scrt507 · Cited by 110 · cited 2×
“…a plethora of methods to improve these cells: changing culture surfaces (Zhu et al., 2014), applying biochemical stress by electrical stimulation (Zhu et al., 2014), co-cultures with non-cardiomyocytes (Ravenscroft, Pointon, Williams, Cross, & Sidaway, 2016), over-expression, prolonged cell…”
Cited by
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Cardiomyocyte Maturation: New Phase in Development
Guo, Y., & Pu, W. T. (2020) · Circulation Research · doi:10.1161/circresaha.119.315862 · Cited by 653
Metabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes
Feyen, D. A. M., McKeithan, W. L., Bruyneel, A. A. N., Spiering, S., Hörmann, L., Ulmer, B., Zhang, H., Briganti, F., Schweizer, M., Hegyi, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107925 · Cited by 400
Current methods for the maturation of induced pluripotent stem cell-derived cardiomyocytes
Machiraju, P., & Greenway, S. C. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i1.33 · Cited by 108
Metadata
- Authors
- Goversen, B., van der Heyden, M. A. G., van Veen, T. A. B., & de Boer, T. P.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 183
- Pages
- 127-136
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2763140785
- Cited by
- 164
- References
- 11
- FWCI
- 6.89
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.